Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib
Investegate announcements from Galapagos NV, Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Enrollment is completed for a Phase 3 trial to evaluate the safety and efficacy of alicaforsen in patients with pouchitis, a frequent complication after surgery to treat distinct forms of inflammatory bowel disease, Atlantic Healthcare announced.